<DOC>
	<DOCNO>NCT00861107</DOCNO>
	<brief_summary>This Phase I/II study investigate feasibility create personalize therapeutic cancer vaccine within body . A vaccine contain source tumor antigen adjuvant . In study , tumor antigen generate freezing tumor minimally invasive percutaneous ( skin ) cryoablation procedure . The study drug , AlloStim , inject ablated tumor promote development anti-tumor immune response .</brief_summary>
	<brief_title>In-Situ Therapeutic Cancer Vaccine Metastatic Cancer Combining AlloStim With Tumor Cryoablation</brief_title>
	<detailed_description>This Phase I/II clinical study investigate feasibility create personalize anti-tumor vaccine within body patient advance cancer . The aim study evaluate safety administration anti-tumor effect vaccine protocol three separate phase . Cancer patient generally present immune response cancer bias Th2 response , Th1 response consider necessary mediate anti-tumor immunity . The first step study consist three ( 3 ) weekly intradermal priming dos AlloStim . The aim step create Th1 immunity alloantigens AlloStim , thus increase number Th1 cell circulation . The second step protocol involve cryoablation select tumor lesion follow intratumoral AlloStimTM injection . The aim step generate tumor-specific CTL killer cell circulation . The final step intravenous infusion AlloStim . The aim step activate circulate Th1 cell , killer cell , natural killer cell The aim step create inflammatory environment break-down ability tumor avoid anti-tumor immune response .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 year older Metastatic cancer refractory least one course active chemotherapy prior radiation therapy , include metastatic breast cancer , colorectal cancer , nonsmall cell lung cancer , ovarian gynecological cancer , prostate cancer , pancreatic GI cancer , melanoma , head neck cancer lymphoma/plasmacytoma . Measurable disease determine upon review abdominal and/or chest CT scan within 60 day evaluation study inclusion target tumor lesion cryoablation locate liver , kidney , bone , pancreas , lymph node , skin , neck prostate deem accessible percutaneous access . Acceptable cryoablation procedure technique risk : target tumor ablation must adequate distance adjacent vasculature organ permit safe application cryoprobe ( generally , 2.5cm clearance cryoprobe vital structure bowel , inferior vena cava , aorta ) . The safety assessment cryoprobe placement make attend radiologist base imaging study . Life expectancy &gt; 180 day No bevacizumab ( Avastin® ) within 6 week plan cryoablation procedure ECOG status 01 No concurrent medication know interfere platelet function coagulation ( e.g. , aspirin , ibuprofen , clopidogrel , warfarin ) unless medication discontinue appropriate time period base drug halflife know activity ( e.g. , aspirin 7 day ) prior cryoablation procedure No low molecular weight heparin preparation unless discontinue 8 hour prior cryoablation At least 2 week since prior cytotoxic chemotherapy Absolute granulocyte count ≥ 1,200/mm3 Platelet count ≥ 100,000/mm3 PT/INR ≤ 1.5 INR correctable ≤ 1.5 PT/PTT correctable normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR monitor weekly prior cryoablation day 21 assure INR stable . However , heparin warfarin must withhold prior cryoablation criterion meet . Hemoglobin ≥ 9 g/dL Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 time normal Alkaline phosphatase ≤ 2.5 time normal ( ≤ 5 time normal liver involvement ) Aspartate aminotransferase ( AST ) ( SGOT ) ≤ 2.5 time ULN Alanine aminotransferase ( ALT ) ( SGPT ) ≤ 2.5 time ULN Not pregnant lactate Patients child bear potential must agree use adequate contraception No psychiatric addictive disorder condition , opinion investigator , would preclude study participation Study specific inform consent Taking anticoagulant medication concomitant medical condition ( unless safely discontinue cryoablation procedure ) Prior allogeneic bone marrow/stem cell solid organ transplant Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisone ) within 30 day first day study drug treatment Topical inhale corticosteroid permit Concomitant autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , autoimmune thyroid disease , uveitis ) Prior experimental cancer vaccine treatment ( e.g. , dendritic cell therapy , heat shock vaccine ) Immunosuppressive therapy , include : cyclosporine , antithymocyte globulin , tacrolimus within 3 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>GI cancer</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Kidney cancer</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>type metastatic cancer least one tumor lesion accessable percutaneous cryoablation</keyword>
</DOC>